Puma Biotechnology Sets New 12-Month High at $261.00 (PBYI)
Shares of Puma Biotechnology (NASDAQ:PBYI) reached a new 52-week high on Monday , Analyst RN reports. The stock traded as high as $261.00 and last traded at $260.32, with a volume of 154,291 shares changing hands. The stock had previously closed at $252.72.
Several analysts have recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an “outperform” rating on the stock.
The stock has a 50-day moving average of $150.0 and a 200-day moving average of $105.5. The company’s market cap is $7.886 billion.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.39. Analysts expect that Puma Biotechnology will post $-3.77 EPS for the current fiscal year.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.